Evolution of Naturally Acquired Hepatitis B Immunity in the Long-Term Hemodialysis Population

American Journal of Kidney Diseases

Volumn 42, Issue 6, 2003, Pages 1193-1199

  Charest, Andre F ^b   Grand'Maison, Anne ^b   McDougall, James ^b   Goldstein, Marc B ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b NONE

Author keywords

Antibody (Ab) titer; Booster vaccination; Hepatitis B virus (HBV); Natural immunity

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMODIALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LONG TERM CARE; MALE; PROSPECTIVE STUDY; VACCINATION; VIRUS IMMUNITY;

EID: 0344826840     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2003.08.020     Document Type: Article

References (13)

1. Centers for Disease Control and Prevention: Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Morbid Mortal Wkly Rep 50:1-46, 2001
2. Fraser GM, Ochana N, Fenyves D, et al: Increasing serum creatinine and age reduce the response to hepatitis B vaccine in renal failure patients. J Hepatol 21:450-454, 1994
3. Albertoni F, Battilomo A, DiNardo V, et al: The Latium Hepatitis Prevention Group: Evaluation of a region-wide hepatitis B vaccination program in dialysis patients: Experience in an Italian region. Nephron 58:180-183, 1991
4. Kohler H, Arnold W, Renschin G, Dormeyer HH, Meyerzum Buschenfelde KG: Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 25:124-128, 1984
5. Bruguera M, Rodicio JL, Alcazar JM, Oliver A, Del-Rio G, Estaban-Mur R: Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in hemodialysis patients. Vaccine 8:S47-S49, 1990 (suppl 1)
6. Charest AF, McDougall J, Goldstein MB: A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis 36:976-982, 2000
7. Horowitz MM, Erschler WB, McKinney WP, Battiola RJ: Duration of immunity after hepatitis B vaccination: Efficacy of low-dose booster vaccine. Ann Intem Med 108:185-189, 1988
8. Dentico P, Volpe A, Buongiorno R, et al: Immunogenicity and efficacy of anti-hepatitis B vaccines in hemodialysis patients. Nephron 61:324-325, 1992
9. Lewis-Ximenez LL, Oliveira JM, Mercadante LA, et al: Serological and vaccination profile of hemodialysis patients during an outbreak of hepatitis B virus infection. Nephron 87:19-26, 2001
10. Wainwright RB, McMahon BJ, Bulkow LR, et al: Duration of immunogenicity and efficacy of hepatitis B vaccine in Yupik Eskimo population. JAMA 261:2362-2366, 1989
11. Komori M, Yuki N, Nagaoka T, et al: Long-term clinical impact of occult hepatitis B virus infection in chronic hepatitis B patients. J Hepatol 35:798-804, 2001
12. Noborg U, Gusdal A, Horal P, Lindh M: Levels of viraemia in subjects with serological markers of past or chronic hepatitis B virus infection. Scand J Infect Dis 32:249-252, 2000
13. Waite NM, Thomson LG, Goldstein MB: Successful vaccination with intradermal injection of hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine. J Am Soc Nephrol 5:1930-1934, 1995